Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.

ABSTRACT:

Objectives

To analyse the section of Disclosure UK that pertains to healthcare professionals (HCPs) in order to provide insight into the database's structure and content and suggest ways to improve its transparency.

Design and participants

Cohort study of drug companies and HCPs in the 2015 and 2016 versions of Disclosure UK.

Results

Companies report transfers of value (ToVs) to named HCPs or, where an HCP declines to consent, in aggregate. Only a limited number of variables describe the recipient HCP and the ToV, precluding refined analyses. In 2015, 107 companies reported 54 910 ToVs worth ₤50 967 728. In 2016, 109 companies reported ToVs but spending decreased by 7.3%. The spending was concentrated: the top 10 spenders reported about 50% of the total value, with co

SUBMITTER: Mulinari S 

PROVIDER: S-EPMC6196800 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature